Biomonitor Acquires the Irish Theranostic Company Neutekbio
News Dec 05, 2008
Biomonitor A/S has completed the acquisition of the Irish company Neutekbio Ltd. on 27 November 2008. Neutekbio's technologies and products complement Biomonitor’s current offerings to physicians and clinics involved in treatment of patients with Multiple Sclerosis, Rheumatoid Arthritis and Crohn’s disease worldwide.
Biomonitor will continue the R&D and manufacturing operations in Ireland and the ongoing collaboration with the French research institution CNRS in Paris. CNRS is a leading research organization in cell biology, virology, and medicine.
The acquisition is made possible by the financial support from Sunstone Capital in Denmark. "We are committed to supporting Biomonitor in becoming a leader in monitoring and improving costly protein based therapies - also by acquisition of supplementary products and technologies when possible", says Soren Lemonius, Chairman of Biomonitor and Partner in Sunstone Capital.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE